Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Preliminary Results from a Phase 1 Study of APVO436, a Novel Anti-CD123 x Anti-CD3 Bispecific Molecule, in Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome

Justin M. Watts, MD, Tara Lin, MD, Eunice S. Wang, MD, Alice S. Mims, MD, Elizabeth H. Cull, MD, Prapti A. Patel, MD, Paul J. Shami, MD, Roland B. Walter, MDPhDMS, Christopher R. Cogle, Ruth A. Chenault, MS, Bret Macpherson, MSc, MBA, Allison Given Chunyk, Catherine J. McMahan, Jane A. Gross, PhD, Scott Stromatt, MD

Blood (2020) 136 (Supplement 1): 11–12.

https://doi.org/10.1182/blood-2020-141619

Published: 2020

Journal Articles

Phase 1b Study of TRU-016, an Anti-CD37 SMIP™ Protein, in Combination with Bendamustine Vs Bendamustine Alone in Relapsed Chronic Lymphocytic Leukemia

Farrukh Awan, MD, MS, Ulrich Jaeger, MD, Robert Rifkin, MD, Michael J Thirman, MD, John C. Byrd, MD, Michael Hallek, MD, Scott Stromatt, MD, John M. Pagel, MD, PhD

Blood (2012) 120 (21): 1795.

https://doi.org/10.1182/blood.V120.21.1795.1795

Published: 2012

Journal Articles

Phase 1b Study of TRU-016, an Anti-CD37 SMIP™ Protein, in Combination with Rituximab and Bendamustine in Relapsed Indolent Lymphoma

Ajay K. Gopal, MD, Stefano R Tarantolo, Naresh Bellam, MD, MPH, Tatyana Feldman, MD, Anthony R Mato, MD, Damian J Green, MD, Melissa Griffin, Scott Stromatt, MD, Andre Goy, MD

Blood (2012) 120 (21): 3678.

https://doi.org/10.1182/blood.V120.21.3678.3678

Published: 2012

Journal Articles

Phase 1 Study of TRU-016, An Anti-CD37 SMIP™ Protein in Relapsed and/or Refractory NHL Patients

John M. Pagel, MD, PhD, Stephen Spurgeon, MD, Farrukh Awan, MD, MS, Kristie A. Blum, MD, Mark C Lanasa, MD, PhD, Ian W. Flinn, MD, PhD, Scott Stromatt, MD, John C. Byrd, MD, Ajay K. Gopal, MD

Blood (2011) 118 (21): 1636.

https://doi.org/10.1182/blood.V118.21.1636.1636

Published: 2011

Journal Articles

Phase 1 Study of Tru-016, An Anti-CD37 SMIP™ Protein in Naïve and Relapsed and/or Refractory CLL Patients

Farrukh T Awan, MD, MS, John M. Pagel, MD, PhD, Leslie A Andritsos, MD, Ajay K. Gopal, MD, Richard R. Furman, MD, Stephen Spurgeon, MD, Delva Deauna-Limayo, MD, Scott Stromatt, MD, John C. Byrd, MD

Blood (2011) 118 (21): 1792.

https://doi.org/10.1182/blood.V118.21.1792.1792

Published: 2011

Journal Articles

Pro-Apoptotic Effect of An Anti-CD37 Scfv-Fc Fusion Protein, in Combination with the Anti-CD20 Antibody, Ofatumumab, on Tumor Cells From B-Cell Malignancies

Piotr Smolewski, Robak Pawel, Barbara Cebula-Obrzut, Malgorzata Misiewicz, Aleksandra Jeske, Agata Majchrzak, Scott Stromatt, MD, Tadeusz Robak

Blood (2011) 118 (21): 1662.

https://doi.org/10.1182/blood.V118.21.1662.1662

Published: 2011

Journal Articles

Tetraspanin CD37 Directly Mediates Transduction of Survival and Apoptotic Signals

Rosa Lapalombella, PhD, Asha Ramanunni, MD, Yuh-Ying Yeh, PhD, Liwen Wang, PhD, Shruti Jha, Justin Staubli, Sarah E. M. Herman, PhD, Leslie A Andritsos, MD, Jeffrey A. Jones, MD, MPH, Joseph M. Flynn, DO, MPH, Xiaokui Mo, PhD, MAS, Amy J. Johnson, PhD, Peter Thompson, MD, Paul A. Algate, PhD, Scott Stromatt, MD, Michael A Freitas, Ph.D., Natarajan Muthusamy, DVM, Ph.D, John C. Byrd, MD

Blood (2011) 118 (21): 622.

https://doi.org/10.1182/blood.V118.21.622.622

Published: 2011

Journal Articles

A Phase 1 Trial of TRU-016, An Anti-CD37 Small Modular Immunopharmaceutical (SMIP TM ) Protein in Relapsed and Refractory CLL: Early Promising Clinical Activity.

Leslie Andritsos, MD, Richard R Furman, Ian W Flinn, Andres Foreno-Torres, M.D., Joseph M. Flynn, DO, MPH, FACP, Natarajan Muthusamy, PhD, Sarwish Rafiq, MS, Scott Stromatt, MD, John C. Byrd

Blood (2009) 114 (22): 3424.

https://doi.org/10.1182/blood.V114.22.3424.3424

Published: 2009

Journal Articles

Results of a Phase II Study of Pixantrone in Combination with Cyclophosphamide, Vincristine, and Prednisone in Patients with Relapsed Aggressive Non-Hodgkin’s Lymphoma.

Peter Borchmann, MD, Raoul Herbrecht, MD, Martin Wilhelm, Franck Morschhauser, MD, Georg Hess, MD, Klaus Kutz, Scott Stromatt, MD, Andreas Engert, MD

Blood (2006) 108 (11): 529.

https://doi.org/10.1182/blood.V108.11.529.529

Published: 2006

Journal Articles

Results of a Phase I/II Trial of Pixantrone in Combination with Fludarabine, Dexamethasone, and Rituximab in the Treatment of Patients with Relapsed/Refractory Indolent Non-Hodgkin’s Lymphoma (NHL).

Luis Fayad, MD, James Liebmann, MD, Manuel Modiano, MD, Gary Cohen, MD, Barbara Pro, MD, Jorge Romaguera, MD, Scott Stromatt, MD

Blood (2006) 108 (11): 2758.

https://doi.org/10.1182/blood.V108.11.2758.2758

Published: 2006

NARROW

Preliminary Results from a Phase 1 Study of APVO436, a Novel Anti-CD123 x Anti-CD3 Bispecific Molecule, in Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome

Phase 1b Study of TRU-016, an Anti-CD37 SMIP™ Protein, in Combination with Bendamustine Vs Bendamustine Alone in Relapsed Chronic Lymphocytic Leukemia

Phase 1b Study of TRU-016, an Anti-CD37 SMIP™ Protein, in Combination with Rituximab and Bendamustine in Relapsed Indolent Lymphoma

Phase 1 Study of TRU-016, An Anti-CD37 SMIP™ Protein in Relapsed and/or Refractory NHL Patients

Phase 1 Study of Tru-016, An Anti-CD37 SMIP™ Protein in Naïve and Relapsed and/or Refractory CLL Patients

Pro-Apoptotic Effect of An Anti-CD37 Scfv-Fc Fusion Protein, in Combination with the Anti-CD20 Antibody, Ofatumumab, on Tumor Cells From B-Cell Malignancies

Tetraspanin CD37 Directly Mediates Transduction of Survival and Apoptotic Signals

A Phase 1 Trial of TRU-016, An Anti-CD37 Small Modular Immunopharmaceutical (SMIP TM ) Protein in Relapsed and Refractory CLL: Early Promising Clinical Activity.

Results of a Phase II Study of Pixantrone in Combination with Cyclophosphamide, Vincristine, and Prednisone in Patients with Relapsed Aggressive Non-Hodgkin’s Lymphoma.

Results of a Phase I/II Trial of Pixantrone in Combination with Fludarabine, Dexamethasone, and Rituximab in the Treatment of Patients with Relapsed/Refractory Indolent Non-Hodgkin’s Lymphoma (NHL).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only